ReviewScience China. Life sciences2026
Liposomes in tumor treatment: a double-edged sword.
Review in Science China. Life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While FDA-approved liposomal drugs (e.g., Doxil®) have demonstrated improved toxicity profiles and targeted delivery, emerging evidence reveals paradoxical pro-angiogenic and immunosuppressive effects that compromise therapeutic outcomes. This review examines the critical yet underappreciated role of complement system activation in mediating these adverse effects. We present a comprehensive analysis of the dynamic interactions between liposomal formulations, complement proteins, and the tumor microenvironment. By elucidating these mechanisms, we identify key challenges and opportunities for optimizing nanocarrier design. Our synthesis provides a framework for developing next-generation liposomal therapeutics with enhanced efficacy and reduced immunogenic potential, offering important insights for translational cancer nanomedicine.
Indexed as
Identifiers
41557109What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.